AXGNAxogen, Inc.
Is the price fair?
Priced for +42% a year vs +19% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~42% a year FCF growth. The price demands more than its three-year revenue growth of 19% a year, priced for acceleration.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AXGN's price assumes
Axogen, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 9.42× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.36%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +42%
Growth the price implies · The price pays for +42% free cash flow growth a year for a decade; revenue has grown +19% a year over the last three.
- Price / book
- 9.23
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 9.23
- EV / EBIToperating margin −5.1%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 8.98
- Free cash flow, trailing twelve months
- $8.6M
- Market capitalisation
- $2.37B
- 3-year revenue growth
- +19%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.